AJP - Heart Information on EB 2010
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 277: H1113-H1118, 1999;
0363-6135/99 $5.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Domoki, F.
Right arrow Articles by Busija, D. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Domoki, F.
Right arrow Articles by Busija, D. W.
Vol. 277, Issue 3, H1113-H1118, September 1999

Cycloheximide rapidly inhibits cortical COX activity and COX-dependent pial arteriolar dilation in piglets

Ferenc Domoki1,4, James V. Perciaccante2, Roland Veltkamp1,3, Greg Robins1, Ferenc Bari1,4, Thomas M. Louis5, and David W. Busija1

1 Department of Physiology and Pharmacology, 2 Department of Pediatrics, and 3 Stroke Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27157-1010; 4 Department of Physiology, Albert Szent-Györgyi Medical University, Szeged, H-6720 Hungary; and 5 Department of Anatomy and Cell Biology, East Carolina University, School of Medicine, Greenville, North Carolina 27858-4353

We have previously shown that cycloheximide (CHX) preserved neuronal function after global cerebral ischemia in piglets, in a manner similar to indomethacin. To elucidate the mechanism of this protection, we tested the hypothesis that CHX would inhibit cyclooxygenase (COX) activity in the piglet cerebral cortex and vasculature. Pial arteriolar responses to hypercapnia, arterial hypotension, and sodium nitroprusside (SNP) were determined before and 20 min after treatment with CHX (0.3-1 mg/kg iv) using a closed cranial window and intravital microscopy. We also determined baseline and arachidonic acid (AA)-stimulated cortical PGF2alpha and 6-keto-PGF1alpha production before and 20-60 min after CHX (1 mg/kg iv) treatment, using ELISA kits. CHX did not affect baseline diameters (~100 µm) but significantly decreased arteriolar dilation to COX-dependent stimuli, such as hypercapnia and hypotension, but not to COX-independent SNP. In the 1 mg/kg CHX-treated group, increases in vascular diameters were reduced from 22 ± 2 to 10 ± 2%, from 49 ± 5 to 31 ± 3% (means ± SE, 5 and 10% CO2, respectively, n = 8), from 12 ± 3 to 3 ± 1%, and from 26 ± 5 to 6 ± 2% (~25 and 40% decreases in blood pressure, respectively, n = 6). CHX also inhibited conversion of exogenous AA to both PGF2alpha and 6-keto-PGF1alpha ; for example, 20 min after CHX treatment 10 µg/ml AA-stimulated PGF2alpha concentrations in the artificial cerebrospinal fluid decreased from 14.28 ± 3.04 to 5.90 ± 1.26 ng/ml (n = 9). Thus CHX rapidly decreases COX activity in the piglet cerebral cortex. This result may explain in part the preservation of neuronal function of CHX in cerebral ischemia.

cerebral blood flow; arachidonic acid; hypercapnia; arterial hypotension; prostaglandin H synthase





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online